The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Rhambo...
again you are wrong and your short positions are burning and rightly so.
The Iclaprim was not rejected by the FDA but they encouraged Motif to carry on with additional trial data before approval.
http://ir.motifbio.com/news-releases/news-release-details/motif-bio-confirms-meeting-date-us-fda-regarding-iclaprim
Your tactics are not working....Try harder next time .
What an excellent and suitable name. Rumpwipe (r)
Apologies meant rhomboid not rumwipe, my predictive text is pretty good though
Rejected ! Shows how little you actually know, stick to the facts Rumwipe.
Rhambo- first thing is, Iclaprim hasn't been rejected or it would have been lights out back in May .
Second, had there been no way forward and no viable plan, Hercules would've pulled the plug and not have been working with MOTIF.
Third- As much as the funding situation has not been resolved, I believe that there are funding options for late stage development. So as much as this is a risk, people who I best in these types of companies understand the risk, but if/when this is resolved, the upside would significantly outweigh the risk.
For the reason mentioned, if you haven't already done any research and can't afford the risk, then maybe the stock market isn't the place to invest.
Now- reading your last post would, you most definitely sound like you haven't even got a single share here, so why bother warning people who are here and who have done their reaearch?
People may be underwater, and many people have sold, but believe me that those who are here and those who are currently building a position know the possible returns!
You guys have lost it. Have you forgotten your drug has been rejected and you're out of cash at some point in the next 5 weeks. You better be praying Hercules doesn't pull the plug on you next week
Hello everyone-
Wisha- it seems like there is more action in the UK side.
To me it looks like the MM's are possibly working some buys to report later. So, far the signs seem to be positive... Starting with the most recent RNs and the slow yet positive growth in buys that have moved things a little more north.
It seems to me that people are cautiously optimistic and are willing to start coming in at these levels.
US investors starting to wake up to the opportunity on offer.
Volume increasing over the pond and rightly so..
Not long till the meeting and potentially any other news
To add- mms / DMAs acting dfferently yesterday and so far today.
100k sell at opening 2.31 , now 2.58 - the usual 45 min silent shake
But dummy for 1.5m sell yesterday was 1.974 - unheard of both Re price and actually getting a quote for that size.
So, educated punt time imo.
Level 2 set up for a run to 3p..
Graham will unleash the beast soon....
Agree that the last RNS was very encouraging - its taking MTFB seriously and US gov. participation and funded.
Its still a punt for PIs as we don't know what is going on but at least what we do know is so far positive - all you can go on if you want to buy.
Imo...perfect time to add more here..
No chance of going bust.....blockbuster AB with its dire needs in many health conditions with many interested parties including usa health institutional recent funding
Share upside in big way is coming.
Holding just over 2m shares .
DYOR